This company’s fight against the misunderstood and misdiagnosed ⚔️

Sponsored by: Hello investors – hanging in there?  I feel you! Not only has the market been one huge epic battle this year, scientists fighting autoimmune diseases have lived this reality for decades.  Autoimmune diseases have been called “illnesses of the unknown” -- the body attacks itself, the resulting illnesses tend to be consistently misdiagnosed, and few effective treatments exist even after proper diagnosis. There are more than 80 believed autoimmune illnesses including diabetes, multiple sclerosis and rheumatoid arthritis.  So what does cause a person’s body to attack itself? And why is a particular tissue selected as the target? These questions have completely stumped scientists, but have not thwarted them from throwing everything including the kitchen sink to answer them.  Which brings us to one of our favorite biotechs -- [MyMD]( -- right there in the meat grinder with its leading drug candidate, MYMD-1®, waging the fight against autoimmune diseases.  [MYMD](-1® being designed as a weapon to defend the body from attacking itself.  To understand the potential of this life-altering drug, we invite you to watch [MyMD](’s short and easy-to-understand (even for the science challenged) video [HERE](. In case you are like me and want to skip straight to the highlights, the video states, “Most autoimmune diseases are treated by alleviating symptoms rather than addressing the underlying causes. [...] Unlike other TNF-alpha drugs, MYMD-1® is designed to stop the underlying causes of chronic inflammatory disease.”  To reiterate, [MYMD](-1® is not only being designed to reduce symptoms but to STOP the underlying causes of chronic inflammatory diseases.  Further, the company video overviews its research, pointing to the potential of [MYMD](-1®, stating, “Overall, these studies suggest that [MYMD](-1®could be used to regulate the overly active immune responses in patients with auto-immune diseases.”  Also, did you catch the wild trading action last week for [MYMD](? We saw a wild 15% swing from the morning lows. This stock has now tested the low $2’s a couple of times in the last month. Assuming those low prints do indeed hold up, I think we have a very nice tradeable bottom to work from now.  To better understand this potentially of this life-altering drug, we invite you take a look [HERE](. See Disclaimers Below 62 Calef Hwy #233 Lee, New Hampshire 03861 United States Questions or concerns about our products? Email us at [Support@ragingbull.com](mailto:/Support@ragingbull.com) © Copyright 2022, [RagingBull]( - [Refund Policy]( - [Privacy Policy]( - [Terms & Conditions](  *THIS IS AN ISSUER-PAID ADVERTISEMENT, SEE DISCLOSURE BELOW*ISSUER-PAID ADVERTISEMENT. MyMD, Inc. (“MYMD” or the “Company”) HAS PAID ORWILL PAY SHERWOOD VENTURES, LLC (“Sherwood”) TWENTY-THOUSAND DOLLARS USD PER MONTH FOR THREE MONTHS (THE “INITIAL TERM”) IN CASH, SHARES OF RESTRICTED COMMON STOCK WITH A VALUE OF ONE-HUNDRED-FIFTY THOUSAND DOLLARS, AND WARRANTS VALUED AT ISSUANCE OF SEVENTY-FIVE THOUSAND DOLLARS FOR MARKETING SERVICES INCLUDING COMMUNICATING TO THE PUBLIC ABOUT THE COMPANY THROUGH SHERWOOD’S AFFILIATE RAGINGBULL.COM, LLC (“RAGING BULL”), AMONG OTHERS. THIS ADVERTISEMENT IS PART OF THOSE ISSUER-PAID MARKETING SERVICES. FOR DETAILED COMPENSATION AND MORE INFORMATION, PLEASE SEE THE FULL DISCLOSURE LOCATED AT HTTPS://BOARDROOMINVESTING.COM/MYMD-DISCLAIMER. DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at [(. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of [RagingBull.com](, LLC are paid in whole or in part by commission based on their sales of Services to subscribers. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. [Manage your email subscriptions.](